Avidity Biosciences, Inc. - SIC # 2836 - BIOLOGICAL PRODUCTS, EXCEPT DIAGNOSTIC SUBSTANCES

Ticker Exchange SIC # Website Latest Ticker
RNA Nasdaq 2836 www.aviditybiosciences.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Avidity Biosciences, Inc.

Avidity Biosciences First Quarter 2025 Earnings: Misses Expectations - May 10th, 2025 12:32 pm
Avidity Biosciences, Inc. (RNA) Reports Q1 Loss, Misses Revenue Estimates - May 8th, 2025 9:55 pm
Avidity Biosciences Reports First Quarter 2025 Financial Results and Recent Highlights - May 8th, 2025 8:05 pm
Avidity Biosciences to Participate in Upcoming Investor Conference - May 6th, 2025 1:00 pm
Trump’s FDA Sends a Bullish Signal to Biotech - Apr 22nd, 2025 9:30 am
Why Sarepta Therapeutics And Other Genetics Stocks Just Got A Sizable Boost - Apr 21st, 2025 8:09 pm
Avidity Biosciences Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Apr 21st, 2025 8:05 pm
Avidity Biosciences Receives Orphan Drug Designation in Japan for Delpacibart Etedesiran (del-desiran) for Treatment of Myotonic Dystrophy Type 1 - Apr 8th, 2025 1:00 pm
Avidity Biosciences (RNA): Among Unstoppable Stocks That Could Double Your Money - Apr 5th, 2025 9:22 pm
Avidity Biosciences (RNA) Soars 11.3%: Is Further Upside Left in the Stock? - Apr 3rd, 2025 1:34 pm
Biotech stocks slide as Marks resignation seen being negative for sector - Apr 1st, 2025 3:50 pm
Avidity Biosciences Completes Enrollment in Biomarker Cohort in Phase 1/2 FORTITUDE™ Trial for Delpacibart Braxlosiran (del-brax) in People Living with Facioscapulohumeral Muscular Dystrophy - Mar 31st, 2025 1:00 pm
Avidity Biosciences Announces Positive Topline Del-zota Data Demonstrating Consistent, Statistically Significant Improvements in Dystrophin, Exon Skipping and Creatine Kinase in People Living with Duchenne Muscular Dystrophy Amenable to Exon 44 Skipping in Phase 1/2 EXPLORE44® Trial - Mar 17th, 2025 11:00 am
Avidity Biosciences Announces Upcoming Presentations at the Muscular Dystrophy Association (MDA) Clinical & Scientific Conference - Mar 12th, 2025 8:05 pm
Avidity Biosciences Full Year 2024 Earnings: Revenues Beat Expectations, EPS In Line - Mar 1st, 2025 12:05 pm
Avidity Biosciences Honors Rare Disease Day® and Global Efforts to Support People and Families Impacted by Rare Neuromuscular Diseases - Feb 28th, 2025 2:00 pm
Avidity Biosciences, Inc. (RNA) Reports Q4 Loss, Tops Revenue Estimates - Feb 27th, 2025 10:40 pm
Avidity Biosciences to Participate in Upcoming Investor Conferences - Feb 25th, 2025 2:00 pm
We're Hopeful That Avidity Biosciences (NASDAQ:RNA) Will Use Its Cash Wisely - Jan 29th, 2025 3:40 pm
Avidity Biosciences, Inc. (RNA): The Biotech Stock with Biggest Upside Potential - Jan 17th, 2025 4:06 pm